SCHEMBL22070646

SCHEMBL22070646

CCOC(=O)c1cccc(-c2cccc(CO)c2)n1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.59
MAPT P10636 1/20 0.49
PTGER4 P35408 2/20 0.44
CDC7 O00311 2/20 0.43
DBF4 Q9UBU7 2/20 0.43
TRPM8 Q7Z2W7 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
GABRA2 P47869 2/20 0.42
GABRB2 P47870 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CNR2 P34972 1/20 0.42
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
HPGD P15428 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22070955 0.83 CYP1A2 (0.51) CYP1A2MAPTSMN1; SMN2POLBGABRA2
SCHEMBL6447808 0.83 SMN1; SMN2 (0.61) CYP1A2MAPTSMN1; SMN2POLBGABRA2
SCHEMBL10507044 0.79 CYP1A2 (0.68) CYP1A2MAPTTRPM8SMN1; SMN2GABRA2
SCHEMBL1996600 0.79 CYP4F2 (0.61) MAPTSMN1; SMN2POLBALDH1A1CYP4F2
SCHEMBL20730226 0.79 CYP1A2 (0.59) CYP1A2MAPTCDC7DBF4TRPM8
SCHEMBL6432573 0.79 MAPT (0.65) CYP1A2MAPTALDH1A1
SCHEMBL8258783 0.78 CYP1A2 (0.62) CYP1A2MAPTTRPM8POLBGABRA2
SCHEMBL2835370 0.78 CYP1A2 (0.66) CYP1A2MAPTPOLBGABRA2GABRB2
SCHEMBL22939583 0.76 CYP1A2 (0.59) CYP1A2MAPTSMN1; SMN2POLBGABRA2
SCHEMBL1478915 0.76 CYP1A2 (1.00) CYP1A2MAPTSMN1; SMN2POLBGABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 US disclosed
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 US disclosed
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE TAISHO PHARMACEUTICAL CO., LTD (JP) 2021-04-29 US disclosed
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE TAISHO PHARMACEUTICAL CO., LTD (JP) 2021-04-29 US disclosed
EP-3666766-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE Taisho Pharmaceutical Co., Ltd. (JP) 2020-06-17 EP disclosed
EP-3666766-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE Taisho Pharmaceutical Co., Ltd. (JP) 2020-06-17 EP disclosed
CN-110914254-A Azole-substituted pyridine compound 大正制药株式会社 2020-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE CYP2C19, CYP4A11, CYP11B1 CYP1A2 26/4885MAPT 4621/4885PTGER4 186/4885
US-11365192-B2 Pyridine compound substituted with azole CYP2C19, CYP4A11, CYP11B1 CYP1A2 26/4885MAPT 4621/4885PTGER4 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.